>
Neovacs SA logo

ALNEV - Neovacs SA Share Price

€0.014 0.0  5.1%

Last Trade - 14/04/21

Sector
Healthcare
Size
Micro Cap
Market Cap £2.14m
Enterprise Value £2.02m
Revenue £n/a
Position in Universe 828th / 846
Bullish
Bearish
Unlock ALNEV Revenue
Momentum
Relative Strength (%)
1m -37.7%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -95.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
0.007
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.14 0.15 0.015 0.000 0.000 0.000 171.9 -100.0%
+1,508
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Neovacs SArevenues was not reported. Net loss increased 71% toEUR6.4M. Higher net loss reflects UnusualExpense/Management increase from EUR8K to EUR4.9M (expense), Write Back on Provisions decrease of 99% to EUR1K (income), Operating Subsidies decrease from EUR85K (income) toEUR0K. Basic Earnings per Share excluding ExtraordinaryItems decreased from -EUR0.03 to -EUR0.04.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ALNEV Revenue Unlock ALNEV Revenue

Net Income

ALNEV Net Income Unlock ALNEV Revenue

Normalised EPS

ALNEV Normalised EPS Unlock ALNEV Revenue

PE Ratio Range

ALNEV PE Ratio Range Unlock ALNEV Revenue

Dividend Yield Range

ALNEV Dividend Yield Range Unlock ALNEV Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ALNEV EPS Forecasts Unlock ALNEV Revenue
Profile Summary

Neovacs SA is a France-based company active in the biotechnology industry. It specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The Company researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The Company focuses its development effort on two Kinoids for Crohn’s disease, Rheumatoid Arthritis and lupus disease. Neovacs SA’s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The Company operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated November 1, 1992
Public Since April 15, 2010
No. of Shareholders: n/a
No. of Employees: 15
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Euronext - Paris
Shares in Issue 180,127,218
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ALNEV Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ALNEV
Upcoming Events for ALNEV
Friday 17th September, 2021 Estimate
Neovacs SA Annual Shareholders Meeting
Frequently Asked Questions for Neovacs SA
What is the Neovacs SA share price?

As of 14/04/21, shares in Neovacs SA are trading at €0.014, giving the company a market capitalisation of £2.14m. This share price information is delayed by 15 minutes.

How has the Neovacs SA share price performed this year?

Shares in Neovacs SA are currently trading at €0.014 and the price has moved by -76.38% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Neovacs SA price has moved by -81.54% over the past year.

What are the analyst and broker recommendations for Neovacs SA?

Of the analysts with advisory recommendations for Neovacs SA, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Neovacs SA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Neovacs SA next release its financial results?

Neovacs SA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Neovacs SA dividend yield?

Neovacs SA does not currently pay a dividend.

Does Neovacs SA pay a dividend?

Neovacs SA does not currently pay a dividend.

When does Neovacs SA next pay dividends?

Neovacs SA does not currently pay a dividend.

How do I buy Neovacs SA shares?

To buy shares in Neovacs SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Neovacs SA?

Shares in Neovacs SA are currently trading at €0.014, giving the company a market capitalisation of £2.14m.

Where are Neovacs SA shares listed? Where are Neovacs SA shares listed?

Here are the trading details for Neovacs SA:

Country of listing: France
Exchange: PAR
Ticker Symbol: ALNEV
What kind of share is Neovacs SA?

Based on an overall assessment of its quality, value and momentum, Neovacs SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Neovacs SA share price forecast 2021?

Shares in Neovacs SA are currently priced at €0.014. At that level they are trading at 2.82% discount to the analyst consensus target price of 0.00.

Analysts covering Neovacs SA currently have a consensus Earnings Per Share (EPS) forecast of 0.12 for the next financial year.

How can I tell whether the Neovacs SA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neovacs SA. Over the past six months, the relative strength of its shares against the market has been -79.78%. At the current price of €0.014, shares in Neovacs SA are trading at -76.68% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Neovacs SA PE Ratio?

We were not able to find PE ratio data for Neovacs SA.

Who are the key directors of Neovacs SA?

Neovacs SA's management team is headed by:

Bernard Fanget - VPR
Olivier Dhellin - OTH
Jean-Jacques Bertrand - CHM
Daniel Zagury - DRC
Patrick Valroff - IND
Arlene Morris - IND
Therese Croughs - OTH
Vincent Serra - CEO
Valerie Salentey - GCN
Jacques Banchereau - DRC
Muriel Haim - IND
Who are the major shareholders of Neovacs SA?

Here are the top five shareholders of Neovacs SA based on the size of their shareholding:

Neovacs SA Managers and Directors Corporation
Percentage owned: 0.12% (1.36m shares)
Novartis Venture Fund Venture Capital
Percentage owned: 0.11% (1.24m shares)
Participations Besançon Holding Company
Percentage owned: 0.07% (871k shares)
APICAP S.A.S. Investment Advisor
Percentage owned: 0.05% (616k shares)
Neovacs SA Founders Corporation
Percentage owned: 0.03% (381k shares)
Similar to ALNEV
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.